Your browser doesn't support javascript.
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.
Kronbichler, Andreas; Anders, Hans-Joachim; Fernandez-Juárez, Gema Maria; Floege, Jürgen; Goumenos, Dimitrios; Segelmark, Mårten; Tesar, Vladimir; Turkmen, Kultigin; van Kooten, Cees; Bruchfeld, Annette.
  • Kronbichler A; Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
  • Anders HJ; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Fernandez-Juárez GM; Division of Nephrology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Munich, Germany.
  • Floege J; Department of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
  • Goumenos D; Division of Nephrology, RTWH Aachen University Hospital, Aachen, Germany.
  • Segelmark M; Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece.
  • Tesar V; Division of Nephrology, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden.
  • Turkmen K; Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • van Kooten C; Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey.
  • Bruchfeld A; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Nephrol Dial Transplant ; 2021 Mar 09.
Article in English | MEDLINE | ID: covidwho-1123332
ABSTRACT
Coronavirus Disease 19 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of SARS-CoV-2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs. Here, members of the Immunonephrology Working Group (IWG) of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) discuss thirteen frequently-asked questions regarding safety and efficacy of the most promising vaccine candidates. Post-marketing surveillance should be performed to estimate the rate of vaccine response (humoral and cellular) of different vaccine platforms, and surveillance of disease activity following administration of COVID-19 vaccines. Some of the candidates induce signaling pathways which also promote autoimmune kidney diseases, e.g. type I interferons in systemic lupus erythematosus. Efficacy estimates would thus far favor the use of selected COVID-19 vaccines, such as BNT162b2, mRNA-1273 or Gam-COVID-Vac. Humoral immune response after vaccination should be monitored using appropriate assays. Even in the absence of neutralizing antibodies patients might be protected by a sufficient cellular immune response capable to reduce severity of COVID-19. A reduced vaccine response after the use of CD20-depleting agents is anticipated, and it is particularly important to discuss strategies to improve vaccine response with these patients. Distancing and shielding measures remain important as not all vaccines fully protect from coronavirus infection. In-depth information about the most pressing vaccine questions is essential to reduce vaccine hesitancy of patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal subject: Nephrology / Transplantation Year: 2021 Document Type: Article Affiliation country: Ndt

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal subject: Nephrology / Transplantation Year: 2021 Document Type: Article Affiliation country: Ndt